Blood glucose giant Dexcom has used CES 2024 to announce a new continuous glucose monitor (CGM) designed specifically for Type 2 diabetics who don’t use insulin – Dexcom Stelo. The Stelo still ...
DexCom showed strong growth, margin expansion, and Stelo's OTC launch unlocked new markets despite competitive and regulatory ...
The Dexcom Stelo Glucose Biosensor System is an integrated CGM intended for people 18 and older who do not use insulin. Stelo is a small, gray device worn on the upper arm, about the size of a quarter ...
DexCom, Inc. DXCM announced that its DexCom ONE continuous glucose monitoring (CGM) system has been launched in France for people with diabetes. The latest CGM sensor from the company’s portfolio has ...
Dexcom's Stelo is not for individuals with low blood sugar as the system is not designed to alert the user to this condition. Stelo cleared for use without a prescription will provide an option for ...
DexCom’s Fair Value Estimate has recently been revised downward, moving modestly from $102.08 to $100.54 per share. This change reflects subtle shifts in analyst sentiment. While the company still ...
DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ ...
A pending decision by Medicare could double the number of patients eligible for reimbursement for continuous glucose monitoring systems. The catalyst that sent the medical device maker higher was a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback